Article | Published:

Multiple myeloma gammopathies

Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

Abstract

We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5:e365.

  2. 2.

    Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204:3–12.

  3. 3.

    Munshi NFlsd1C, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res. 2011;17:1234–42.

  4. 4.

    Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.

  5. 5.

    Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (mgus) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–7.

  6. 6.

    Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc. 2010;85:933–42.

  7. 7.

    Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.

  8. 8.

    Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114:785–90.

  9. 9.

    Eriksson M, Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control. 1992;3:63–67.

  10. 10.

    Judson IR, Wiltshaw E, Newland AC. Multiple myeloma in a pair of monozygotic twins: the first reported case. Br J Haematol. 1985;60:551–4.

  11. 11.

    Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, et al. Familial myeloma. N Engl J Med. 2008;359:152–7.

  12. 12.

    Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B, Weisenburger DD. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst. 2001;93:1479–83.

  13. 13.

    Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Isgur Bergsagel K, et al. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol. 2005;23:685–93.

  14. 14.

    Bizzaro N, Pasini P. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings. Haematologica. 1990;75:58–63.

  15. 15.

    Zawadzki ZA, Aizawa Y, Kraj MA, Haradin AR, Fisher B. Familial immunopathies: report of nine families and survey of literature. Cancer. 1977;40:2094–101.

  16. 16.

    Ogmundsdottir HM, Einarsdottir HK, Steingrimsdottir H, Haraldsdottir V. Familial predisposition to monoclonal gammopathy of unknown significance, Waldenstrom’s macroglobulinemia, and multiple myeloma. Clin Lymphoma Myeloma. 2009;9:27–29.

  17. 17.

    Ogmundsdottir HM, Haraldsdottirm V, Johannesson GM, Olafsdottir G, Bjarnadottir K, Sigvaldason H, et al. Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica. 2005;90:66–71.

  18. 18.

    Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8406 multiple myeloma patients: a population-based case-control study. Int J Cancer. 2006;118:3095–8.

  19. 19.

    Camp NJ, Werner TL, Cannon-Albright LA. Familial myeloma. N Engl J Med. 2008;359:1734–5. author reply 1735

  20. 20.

    Brown LM, Linet MS, Greenberg RS, Silverman DT, Hayes RB, Swanson GM, et al. Multiple myeloma and family history of cancer among blacks and whites in the u.S. Cancer. 1999;85:2385–90.

  21. 21.

    Bourguet CC, Grufferman S, Delzell E, DeLong ER, Cohen HJ. Multiple myeloma and family history of cancer. A case-control study. Cancer. 1985;56:2133–9.

  22. 22.

    Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600–8.

  23. 23.

    Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in sweden. Blood. 2009;114:791–5.

  24. 24.

    Kristinsson SY, Bjorkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in sweden. Int J Cancer. 2009;125:2147–50.

  25. 25.

    Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120(Suppl 12):40–61.

  26. 26.

    Frank C, Fallah M, Chen T, Mai EK, Sundquist J, Forsti A, et al. Search for familial clustering of multiple myeloma with any cancer. Leukemia. 2016;30:627–32.

  27. 27.

    Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012;119:5359–66.

  28. 28.

    Evans DG, Ingham SL. Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. Appl Clin Genet. 2013;6:53–61.

  29. 29.

    Wilding A, Ingham SL, Lalloo F, Clancy T, Huson SM, Moran A, et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet. 2012;49:264–9.

  30. 30.

    Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia. 2014;28:398–403.

  31. 31.

    Schmidt-Hieber M, Gutierrez ML, Perez-Andres M, Paiva B, Rasillo A, Tabernero MD, et al. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica. 2013;98:279–87.

  32. 32.

    Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100–5.

  33. 33.

    Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:719–34.

  34. 34.

    Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, et al. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013;98:1586–92.

  35. 35.

    Greenberg AJ, Cousin M, Kumar S, Ketterling RP, Knudson RA, Larson D, et al. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. Eur J Haematol. 2013;91:193–5.

  36. 36.

    World Medical Association. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191–4.

  37. 37.

    Dong H, Yang HS, Jagannath S, Stephenson CF, Brenholz P, Mazumder A, et al. Risk stratification of plasma cell neoplasm: Insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cig fish) vs. Conventional fish. Clin Lymphoma Myeloma Leuk. 2012;12:366–74.

  38. 38.

    Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines. Mayo Clin Proc. 2009;84:1095–110.

  39. 39.

    Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–19.

  40. 40.

    Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer. 2006;42:1661–70.

  41. 41.

    Hemminki K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer. 2004;108:109–14.

  42. 42.

    Deshpande HA, Hu XP, Marino P, Jan NA, Wiernik PH. Anticipation in familial plasma cell dyscrasias. Br J Haematol. 1998;103:696–703.

  43. 43.

    Grosbois B, Jego P, Attal M, Payen C, Rapp MJ, Fuzibet JG, et al. Familial multiple myeloma: report of fifteen families. Br J Haematol. 1999;105:768–70.

  44. 44.

    VanValkenburg ME, Pruitt GI, Brill IK, Costa L, Ehtsham M, Justement IT, et al. Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes Control. 2016;27:81–91.

  45. 45.

    Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: results from the international multiple myeloma consortium. Br J Haematol. 2016;175:87–101.

  46. 46.

    Birmann BM, Andreotti G, De Roos AJ, Camp NJ, Chiu BCH, Spinelli JJ, et al. Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the international multiple myeloma consortium (immc). Cancer Epidemiol Biomark Prev. 2017;26:876–85.

  47. 47.

    Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.

  48. 48.

    Morgan GJ, Johnson DC, Weinhold N, Goldschmidt H, Landgren O, Lynch HT, et al. Inherited genetic susceptibility to multiple myeloma. Leukemia. 2014;28:518–24.

  49. 49.

    Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Forsti A, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013;45:1221–5.

  50. 50.

    Weinhold N, Johnson DC, Chubb D, Chen B, Forsti A, Hosking FJ, et al. The ccnd1 c.870g > a polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45:522–5.

  51. 51.

    Broderick P, Chubb D, Johnson DC, Weinhold N, Forsti A, Lloyd A, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet. 2011;44:58–61.

  52. 52.

    Swaminathan B, Thorleifsson G, Joud M, Ali M, Johnsson E, Ajore R, et al. Variants in ell2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun. 2015;6:7213.

  53. 53.

    Scales M, Chubb D, Dobbins SE, Johnson DC, Li N, Sternberg MJ, et al. Search for rare protein altering variants influencing susceptibility to multiple myeloma. Oncotarget. 2017;8:36203–10.

  54. 54.

    Aradóttir KLS, Björkholm M, Goldin LR, Turesson I, Landgren O, Kristinsson SY. Family history of lymphoproliferative disease associated with a superior survival in multiple myeloma: a population-based study. European Hematology Association: Learning Center. 2015.

  55. 55.

    Rosenlof RC, Lemon HM, Rigby PG. Familial factors relating to prognosis of leukemia and lymphoma. Natl Cancer Inst Monogr. 1971;34:283–9.

  56. 56.

    Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1:168–4.

  57. 57.

    Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a seer-medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15:177–86 e174.

  58. 58.

    Gerkes EH, de Jong MM, Sijmons RH, Vellenga E. Familial multiple myeloma: report on two families and discussion of screening options. Hered Cancer Clin Pract. 2007;5:72–78.

  59. 59.

    Wang Q, Wang Y, Ji Z, Chen X, Pan Y, Gao G, et al. Risk factors for multiple myeloma: a hospital-based case-control study in northwest china. Cancer Epidemiol. 2012;36:439–44.

  60. 60.

    Jain M, Ascensao J, Schechter GP. Familial myeloma and monoclonal gammopathy: a report of eight african american families. Am J Hematol. 2009;84:34–38.

Download references

Acknowledgements

We would especially like to acknowledge the many MM/SMM patients and their families who contributed to this research. This work was supported in part by grants R01 CA107476, R01 CA168762, R25 CA092049, and P50 CA186781 (Mayo Clinic Myeloma SPORE) from the National Cancer Institute of the National Institutes of Health and the Mayo Clinic Cancer Center.

Authors' contributions

AICG wrote, reviewed, and edited the original draft, and visualized the tables/figures. SK and SVR helped with conceptualization, methodology, contributed with patients’ samples, provided funding for study, and reviewed/edited. AR helped with data abstraction and reviewed/edited. RAK defined MGUS in first-degree relatives, helped with study methodology, and reviewed/edited. JAK defined MGUS in first-degree relatives and reviewed/edited. DLM contributed to FISH methodology and reviewed/edited. ADN provided project management and reviewed/edited. AJG reviewed/edited. DRL and MMO’B performed statistical analyses and helped with methodology, reviewed/edited, and contributed to visualization of tables/figures. SLS helped with conceptualization and methodology, contributed with patients’ samples, provided funding for the study, reviewed/edited, and supervised research and data analysis. CMV helped with conceptualization and study methodology, defined statistical analytic approach, contributed with patients’ samples, provided funding for the study, reviewed/edited, visualized the tables/figures, and supervised research and data analysis.

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Celine M. Vachon.

Electronic supplementary material

Supplemental Table 1

Supplemental Table 2

Supplemental Table 3

Supplemental Table 4

Supplemental Table 5

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2